Cellular mechanisms underlying the cardiovascular actions of oestrogens

Clinical Science

Volumn 111, Issue 2, 2006, Pages 107-118

  Ling, Shanhong ^a   Komesaroff, Paul ^a   Sudhir, Krishnankutty ^b  

^a MONASH UNIVERSITY   (Australia)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Endothelial cell; Gender associated protection; Oestrogen; Vascular smooth muscle cell

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; GESTAGEN; MOEXIPRILAT; RALOXIFENE; TAMOXIFEN; TIBOLONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CELL FUNCTION; CELL STRUCTURE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; HEART MUSCLE CELL; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR SYSTEM; ENDOTHELIUM, VASCULAR; ESTROGENS; FEMALE; HUMANS; MALE; MICE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, CARDIAC; RECEPTORS, ESTROGEN;

EID: 33747117071     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20050084     Document Type: Review

References (114)

1. Isles, C. G., Hole, D. J., Hawthorne, V. M. and Lever, A. F. (1992) Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: Comparison with men. Lancet 339, 702-706
2. World Health Organization (1996) World Health Annual Statistics 1995, World Health Organization, Geneva
3. Senoz, S., Direm, B., Gulekli, B. and Gokmen, O. (1996) Estrogen deprivation, rather than age, is responsible for the poor lipid profile and carbohydrate metabolism in women. Maturitas 25, 107-114
4. Lip, G. Y., Blann, A. D., Jones, A. F. and Beevers, D. G. (1997) Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am. Heart J. 134, 764-771
5. Stampfer, M. J. and Colditz, G. A. (1991) Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prevent. Med. 20, 47-63
6. Grady, D., Applegate, W., Bush, T., Furberg, C., Riggs, B. and Hulley, S. B. (1998) Heart and Estrogen/Progestin Replacement Therapy (HERS): design, methods, and baseline characteristics. Control Clin. Trials 19, 314-335
7. Hulley, S., Grady, D., Bush, T. et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. JAMA, J. Am. Med. Assoc. 280, 605-613
8. Writing Group for the Women's Health Institutive Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA, J. Am. Med. Assoc. 288, 321-333
9. Knight, D. C. and Eden, J. A. (1995) Phytoestrogens. Maturitas 22, 167-175
10. Simpson, E. R., Zhao, Y., Agarwal, V. R. et al. (1997) Aromatase expression in health and disease. Recent Prog. Horm. Res. 52, 185-213
11. Power, R. F., Mani, S. K., Codina, J., Conneely, O. M. and O'Malley, B. W. (1991) Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 254, 1636-1639
12. Karas, R. H., Gauer, E. A., Bieber, H. E., Baur, W. E. and Mendelsohn, M. E. (1998) Growth factor activation of the estrogen receptor in vascular cells occurs via a mitogen-activated protein kinase-independent pathway. J. Clin. Invest. 101, 2851-2861
13. Kuiper, G. G. J. M., Carlsson, B., Grandien, K. et al. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138, 863-870
14. Grohe, C., Kahlert, S., Lobbert, K. et al. (1997) Cardiac myocytes and fibroblasts also contain functional estrogen receptors. FEBS Lett. 416, 107-112
15. Iafrati, M. D., Karas, R. H., Aronovitz, M. et al. (1997) Estrogen inhibits the vascular injury response in estrogen receptor α-deficient mice. Nat. Med. 3, 545-548
16. Karas, R. H., Hodgin, J. B., Kwoun, M. et al. (1999) Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc. Natl. Acad. Sci. U.S.A. 96, 15133-15136
17. Halachmi, S., Marden, E., Martin, G., MacKay, H., Abbondanza, C. and Brown, M. (1994) Estrogen receptor-associated protein: possible mediators of hormone-induced transcription. Science 264, 1455-1458
18. Shibata, H., Spencer, T. E., Onate, S. A. et al. (1997) Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog. Horm. Res. 52, 141-165
19. Mograno, M. M., Chang, W. and Katzenellenbogen, B. S. (1998) An estrogen receptor-selective corepressor: cloning and characterization. Endocrinology 98, 96
20. Pedram, A., Razandi, M., Aitkenhead, M., Hughes, C. C. W. and Levin, E. R. (2002) Integration of the non-genomic and genomic actions of estrogen: membrane-initiated signaling by steroid to transcription and cell biology. J. Biol. Chem. 277, 50768-50775
21. Sudhir, K., Ko, E., Zellner, C. et al. (1997) Physiological concentrations of estradiol attenuate endothelin-1-induced coronary vasoconstriction in vivo. Circulation 96, 3626-3632
22. Shi, J., Zhang, Y. Q. and Simpkins, J. W. (1997) Effects of 17β-estradiol on glucose transporter 1 expression and endothelial cell survival following focal ischemia in the rats. Exp. Brain Res. 117, 200-206
23. Nathan, L., Pervin, S., Singh, R., Rosenfeld, M. and Chaudhuri, G. (1999) Estradiol inhibits leukocyte adhesion and transendothelial migration in rabbit in vivo: possible mechanisms for gender differences in atherosclerosis. Circ. Res. 85, 377-385
24. Williams, J. K., Adams, M. R. and Klopfenstein, H. S. (1990) Estrogen modulates response of atherosclerotic coronary arteries. Circulation 81, 1680-1687
25. Walsh, B. A., Busch, B. L., Mullick, A. E., Reiser, K. M. and Rutledge, J. C. (1999) 17β-Estradiol reduces glycoxidative damage in the artery wall. Arterioscler., Thromb., Vasc. Biol. 19, 840-846
26. Tse, J., Martin-McNaulty, B., Halks-Miller, M. et al. (1999) Accelerated atherosclerosis and premature calcified cartilaginous metaplasia in the aorta of diabetic male Apo E knockout mice can be prevented by chronic treatment with 17 β-estradiol. Atherosclerosis 144, 303-313
27. Rubanyi, G. M., Freay, A. D., Kauser, K. et al. (1997) Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. Gender difference and effect of estrogen receptor gene disruption. J. Clin. Invest. 99, 2429-2437
28. Mukherjee, T. K., Dinh, H., Chaudhuri, G. and Nathan, L. (2002) Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. 99, 4055-4060
29. Morales, D. E., McGowan, K. A., Grant, D. S. et al. (1995) Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 91, 775-763
30. Piotrowicz, R. S., Weber, L. A., Hickey, E. and Levin, E. G. (1995) Accelerated growth and senescence of arterial endothelial cells expressing the small molecular weight heat-shock protein HSP27. FASEB J. 9, 1079-1084
31. Somjen, D., Kohen, F., Jaffe, A., Amir-Zaltsman, Y., Knoll, E. and Stern, N. (1998) Effects of gonadal steroids and their antagonists on DNA synthesis in human vascular cells. Hypertension 32, 39-45
32. Corvazier, E., Dupuy, E., Dosne, A. M. and Maclouf, J. (1984) Minimal effect of estrogens on endothelial cell growth and production of prostacyclin. Thromb. Res. 34, 303-310
33. Miller, M. E., Dores, G. M., Thorpe, S. L. and Akerley, W. L. (1994) Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions. Thromb. Res. 74, 577-594
34. Drummond, A. E., McPherson, S. J., Laslett, A. and Hearn, M. T. W. (1996) Application of a chromogenic bioassay procedure for the measurement of the proliferation of endothelial cells in vitro under the influence of the effects of steroid hormones and growth factors. J. Biochem. Biophys. Meth. 31, 123-134
35. Alvarez, R. J., Gips, S. J., Moldovan, N. et al. (1997) 17β-Estradiol inhibits apoptosis of endothelial cells. Biochem. Biophys. Res. Commun. 237, 372-381
36. Spyridopoulos, I., Sullivan, A. B., Kearney, M., Isner, J. M. and Losordo, D. W. (1997) Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. Estradiol as a survival factor. Circulation 95, 1505-1514
37. Razandi, M., Pedram, A. and Levin, E. R. (2000) Estrogen signals to the preservation of endothelial cell form and function. J. Biol. Chem. 274, 38541-38546
38. Yue, T. L., Wang, X., Louden, C. S. et al. (1997) 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol. Pharmacol. 51, 951-962
39. Tsukamoto, A., Kaneko, Y., Yoshida, T., Han, K., Ichinose, M. and Kimura, S. (1998) 2-Methoxyestradiol, an endogenous metabolite of estrogen, enhances apoptosis and beta-galactosidase expression in vascular endothelial cells. Biochem. Biophys. Res. Commun. 248, 9-12
40. Nakai, K., Itoh, C., Hotta, K., Itoh, T., Yoshizumi, M. and Hiramori, K. (1994) Estradiol-17β regulates the induction of VCAM-1 mRNA expression by interleukin-1β in human umbilical vein endothelial cells. Life Sci. 54, PL221-PL227
41. Caulin-Glaser, T., Watson, C. A., Pardi, R. and Bender, J. R. (1996) Effects of 17β-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J. Clin. Invest. 98, 36-42
42. Cid, M. C., Kleinman, H. K., Grant, D. S., Schnaper, H. W., Fauci, A. S. and Hoffman, G. S. (1994) Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1. J. Clin. Invest. 93, 17-25
43. Winkler, M., Kemp, B., Hauptmann, S. and Rath, W. (1997) Parturition: steroids, prostaglandin E2, and expression of adhesion molecules by endothelial cells. Obstet. Gynecol. 89, 398-402
44. Simoncini, T., De Caterina, R. and Genazzani, A. R. (1999) Selective estrogen receptor modulators: different actions on vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J. Clin. Endocrinol. Metab. 84, 815-818
45. Simoncini, T., Maffei, S., Basta, G. et al. (2000) Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. Circ. Res. 87, 19-25
46. Hishikawa, K., Nakaki, T., Marumo, T., Suzuki, H., Kato, R. and Saruta, T. (1995) Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett. 360, 291-293
47. Hayashi, T., Yamada, K., Esaki, T. et al. (1995) Estrogen increases endothelial nitric oxide by a receptor-mediated system. Biochem. Biophys. Res. Commun. 214, 847-855
48. Arnal, J. F., Clamens, S., Pechet, C. et al. (1996) Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. Proc. Natl. Acad. Sci. U.S.A. 93, 4108-4113
49. Mendelsohn, M. E. (2000) Nongenomic, ER-mediated activation of endothelial nitric oxide synthase: how does it work? What does it mean? Circ. Res. 87, 956-960
50. Chambliss, K. L. and Shaul, P. W. (2002) Estrogen modulation of endothelial nitric oxide synthase. Endocr. Rev. 23, 665-686
51. Sudhir, K., Chou, T. M., Mullen, W. L. et al. (1995) Mechanisms of estrogen-induced vasodilation: in vivo studies in canine coronary conductance and resistance arteries. J. Am. Coll. Cardiol. 26, 807-814
52. Mikkola, T., Turunen, P., Avela, K., Orpana, A., Viinikka, L. and Ylikorkala, O. (1995) 17β-Estradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells. J. Clin. Endocrinol. Metab. 80, 1832-1836
53. Corvazier, E., Dupuy, E., Dosne, A. M. and Maclouf, J. (1984) Minimal effect of estrogens on endothelial cell growth and production of prostacyclin. Thromb. Res. 34, 303-310
54. Calkin, A. C., Sudhir, K., Honisett, S., Williams, M. R., Dawood, T. and Komesaroff, A. (2002) Rapid potentiation of endothelium-dependent vasodilation by estradiol in postmenopausal women is mediated via cyclooxygenase 2. J. Clin. Endocrinol. Metab. 87, 5072-5075
55. Clowes, A. W., Collazzo, R. E. and Karnovsky, M. J. (1978) A morphologic and permeability study of luminal smooth muscle cells after arterial injury in the rat. Lab. Invest. 39, 141-150
56. Chen, S. J., Chen, Y. F., Miller, D. M., Li, H. B. and Oparil, S. (1994) Mithramycin inhibits myointimal proliferation after balloon injury of the rat carotid artery in vivo. Circulation 90, 2468-2473
57. Chen, S. J., Li, H., Durand, J., Oparil, S. and Chen, Y. F. (1996) Estrogen reduced myointimal proliferation after balloon injury of rat carotid artery. Circulation 93, 577-584
58. Levine, R. L., Chen, S. J., Durand, J., Chen, Y. F. and Oparil, S. (1996) Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of rat carotid artery. Circulation 94, 2221-2227
59. Oparil, S., Levine, R. L., Chen, S. J., Durand, J. and Chen, Y. F. (1997) Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment. Circulation 95, 1301-1307
60. Yue, T. L., Vickery-Clark, L., Louden, C. S. et al. (2000) Selective estrogen receptor modulator idoxifene inhibits smooth muscle cell proliferation, enhances reendothelialization, and inhibits neointimal formation in vivo after vascular injury. Circulation 102 (Suppl. III), III-281-III-288
61. Geary, R. L., Adams, M. R., Benjamin, M. E. and Williams, J. K. (1998) Conjugated equine estrogens inhibit progression of atherosclerosis but have no effect on intimai hyperplasia or arterial remodeling induced by balloon catheter injury in monkeys. J. Am. Coll. Cardiol. 31, 1158-1164
62. Adams, M. R., Kaplan, J. R., Manuck, S. B. et al. (1990) Inhibition of coronary artery atherosclerosis: lack of effect of added progesterone. Arteriosclerosis 10, 1051-1057
63. Fisher-Dzoga, K., Wissler, R. W. and Visselinovitch, D. (1983) The effect of estradiol on the proliferation of rabbit aortic medial tissue culture cells induced by hyperlipidemic serum. Exp. Mol. Pathol. 39, 355-363
64. Karas, R. H., Patterson, B. L. and Mendelsohn, M. E. (1994) Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 89, 1943-1950
65. Morey, A. K., Pedram, A., Razandi, M. et al. (1997) Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology 138, 3330-3339
66. Ling, S., Little, P. J., Williams, M. R. et al. (2002) High glucose abolishes the antiproliferative effect of 17β-estradiol in human vascular smooth muscle cells. Am. J. Physiol. Endocrinol. Metab. 282, E746-E751
67. Suzuki, A., Mizuno, K., Ino, Y. et al. (1996) Effect of 17β-estradiol and progesterone on growth-factor-induced proliferation and migration in human aortic smooth muscle cells in vitro. Cardiovasc. Res. 32, 516-523
68. Dubey, R. K., Jackson, E. K., Gillespie, D. G., Zacharia, L. C., Imthurn, B. and Keller, P. J. (2000) Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity. Artheriosler., Thromb., Vasc. Biol. 20, 964-972
69. Ling, S., Deng, G., Ives, H. E. et al. (2001) Estrogen inhibits mechanical strain-induced mitogenesis in human vascular smooth muscle cells via down-regulation of Sp-1. Cardiovasc. Res. 50, 108-114
70. Dubey, R. K., Gillespie, D. G., Imthurn, B., Rosselli, M., Jackson, E. K. and Keller, P. J. (1999) Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension 33, 177-182
71. Ling, S., Dai, A., Williams, M. R. I. et al. (2004) The isoflavone metabolite cis-tetrahydrodazein inhibits ERK-1 activation and proliferation in human vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 43, 622-628
72. Somjen, D., Knoll, E., Kohen, F. and Stern, N. (2001) Effects of phytoestrogens on DNA synthesis and creatine kinase activity in vascular cells. Am. J. Hypertens. 14, 1256-1262
73. Keyes, L. E., Moore, L. G., Walchak, S. J. and Dempsey, E. C. (1996) Pregnancy-stimulated growth of vascular smooth muscle cells: importance of protein kinase C-dependent synergy between estrogen and platelet-derived growth factor. J. Cell. Physiol. 166, 22-32
74. Ling, S., Dai, A., Dilley, R. J. et al. (2004) Endogenous estrogen deficiency reduces proliferation and enhances apoptosis-related death in vascular smooth muscle cells: insights from the aromatase-knockout mouse. Circulation 109, 537-543
75. Beldekas, J. C., Gerstenfeld, L. C., Sonenshein, G. E. and Franzblau, C. (1982) Cell density and estradiol modulation of procollagen type III in cultured calf smooth muscle cells. J. Biol. Chem. 257, 12252-12256
76. Mizutani, K., Ikeda, K. and Yamori, Y. (2000) Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rates. Biochem. Biophys. Res. Commun. 274, 61-67
77. Chang, W. C., Nakao, J., Orimo, H. and Murota, S. I. (1980) Stimulation of prostaglandin cyclooxygenase and prostacyclin synthetase activities by estradiol in rat aortic smooth muscle cells. Biochem. Biophys. Acta 620, 472-482
78. Steinleitner, A., Stanczyk, F. Z., Levin, J. H. et al. (1989) Decreased in vitro production of 6-keto-prostaglandin F1α by uterine arteries from postmenopausal women. Am. J. Obstet. Gynecol. 161, 1677-1681
79. Voss, M. R., Stalone, J. N., Li, M., Cornelussen, R. N. M., Knuefermann, P. and Knowlton, A. A. (2003) Gender differences in the expression of heat shock proteins: the effect of estrogen. Am. J. Physiol. Heart Circ. Physiol. 285, H687-H692
80. Kam, K. W. L., Qi, J. S., Chen, M. and Wong, T. M. (2004) Estrogen reduces cardiac injury and expression of β1-adrenoceptor upon ischemic insult in the rat heart. J. Pharmacol. Exp. Ther. 309, 8-15
81. Zhai, P., Eurell, T. E., Cooke, P. S., Lubahn, D. B. and Gross, D. R. (2000) Myocardial ischemia-reperfusion injury in estrogen receptor-α knockout and wild-type mice. Am. J. Physiol. Heart Circ. Physiol. 278, H1640-H1647
82. Haunstetter, A. and Izumo, S. (1998) Apoptosis, basic mechanisms and implications for cardiovascular disease. Circ. Res. 82, 1111-1129
83. Pelzer, T., Schumann, M., Neumann, M. et al. (2000) 17β -estradiol prevents programmed cell death in cardiac myocytes. Biochem. Biophys. Res. Commun. 268, 192-200
84. Pelzer, T., Neumann, M., de Jager, T., Jazbutyte, V. and Neyses, L. (2001) Estrogen effects in the myocardium: inhibition of NF-κB DNA binding by estrogen receptor-α and -β. Biochem. Biophys. Res. Commun. 286, 1153-1157
85. Ren, J., Hintz, K. K., Roughead, Z. K. F. et al. (2003) Impact of estrogen replacement on ventricular myocyte contractile function and protein kinase B/Akt activation. Am. J. Physiol. Heart Circ. Physiol. 284, H1800-H1807
86. Rosano, G. M., Leonardo, F., Sarrel, P. M., Beale, C. M., De Luca, F. and Collins, P. (1996) Cyclical variation in paroxysmal supraventricular tachycardia in women. Lancet 347, 786-788
87. Nakajima, T., Iwasawa, K., Oonuma, H. et al. (1999) Antiarrhythmic effect and its underlying ionic mechanism of 17β-estradiol in cardiac myocytes. Br. J. Pharmacol. 127, 429-440
88. Grohe, C, Kahlert, S., Lobbert, K. et al. (1996) Modulation of hypertensive heart disease by estrogen. Steroids 61, 201-204
89. Grohe, C., Kahlert, S., Lobbert, K. et al. (1997) Effects of moexiprilat on oestrogen-stimulated cardiac fibroblast growth. Br. J. Pharmacol. 121, 1350-1354
90. Dubey, R. K., Gillespie, D. G., Jackson, E. K. and Keller, P. J. (1998) 17β-Estradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth. Hypertension 31, 522-528
91. Dubey, R. K., Gillespie, D. G., Zacharia, L. C., Rosselli, M., Imthurn, B. and Jackson, E. K. (2002) Methoxyestradiols mediate the antimitogenic effects of locally applied estradiol on cardiac fibroblast growth. Hypertension 39, 412-417
92. Hu, P., Greendale, G. A., Palla, S. L. et al. (2006) The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis 185, 347-352
93. Vitale, C., Cornoldi, A., Gebara, O. et al. (2005) Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. Menopause 12, 552-558
94. Silvestri, A., Gebara, O., Vitale, C. et al. (2003) Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 107, 3165-3169
95. Cushman, M., Meilahn, E. N., Psaty, B. M., Kuller, L. H., Dobs, A. S. and Tracy, R. P. (1999) Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler., Thromb., Vasc. Biol. 19, 893-899
96. Post, M. S., van der Mooren, M. J., van Baal, W. M. et al. (2003) Effects of two-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study. Am. J. Obstet. Gynecol. 189, 1221-1227
97. Cosman, F., Baz-Hecht, M., Cushman, M. et al. (2005) Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. Thromb. Res. 116, 1-13
98. Dias, Jr, A. R., Melo, R. N., Gebara, O. C. et al. (2005) Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. Climacteric 8, 63-70
99. Yasui, T., Umino, Y., Takikawa, M. et al. (2005) Effects of postmenopausal hormone therapy every day and every other day on lipid levels according to difference in body mass index. Menopause 12, 223-231
100. Shulman, L. P. (2002) Effects of progestins in different hormone replacement therapy formulations on estrogen-induced lipid changes in postmenopausal women. Am. J. Cardiol. 89 (Supp. 1), 47-54
101. Dansuk, R., Unal, O., Karageyim, Y., Esim, E. and Turan, C. (2004) Evaluation of the effect of tibolone and transdermal estradiol on triglyceride level in hypertriglyceridemic and normotriglyceridemic postmenopausal women. Gynecol. Endocrinol. 18, 233-239
102. Jayachandran, M., Mukherjee, R., Steinkamp, T. et al. (2005) Differential effects of 17β-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets. Am. J. Physiol. Heart Circ. Physiol. 288, H2355-H2362
103. de Kraker, A. T., Kenemans, P., Smolders, R. G., Kroeks, M. V. and van der Mooren, M. J. (2004) The effects of 17β-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a). Maturitas 49, 253-263
104. Barrett-Connor, E., Grady, D., Sashegyi, A. et al. (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA, J. Am. Med. Assoc. 287, 847-857
105. Barrett-Connor, E., Cauley, J. A., Kulkarni, P. M., Sashegyi, A., Cox, D. A. and Geiger, M. J. (2004) Risk-benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J. Bone Miner. Res. 19, 1270-1275
106. Keech, C. A., Sashegyi, A. and Barrett-Connor, E. (2005) Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Curr. Med. Res. Opin. 21, 135-140
107. Kimura, M., Sudhir, K., Jones, M., Simpson, E., Jefferis, A. M. and Chin-Dusting, J. P. (2003) Impaired acetylcholine-induced release of nitric oxide in the aorta of male aromatase-knockout mice: regulation of nitric oxide production by endogenous sex hormones in males. Circ. Res. 93, 1267-1271
108. Bagatell, C. J., Knopp, R. H., Rivier, J. E. and Bremner, W. J. (1994) Physiological levels of estradiol stimulate plasma high density lipoprotein2 cholesterol levels in normal men. J. Clin. Endocrinol. Metab. 78, 855-861
109. Smith, E. P., Boyd, J., Frank, G. R. et al. (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331, 1056-1061
110. 109a Mendelsohn, M. E. and Rosano, G. M. C. (2003) Hormonal regulation of normal vascular tone in males. Circ. Res. 93, 1142-1145
111. Sudhir, K., Chou, T. M., Messina, L. M. et al. (1997) Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet 349, 1146-1147
112. Sudhir, K., Chou, T. M., Chatterjee, K. et al. (1997) Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 96, 3774-3777
113. Lew, R., Komesaroff, P., Williams, M., Dawood, T. and Sudhir, K. (2003) Endogenous estrogens influence endothelial function in young men. Circ. Res. 93, 1127-1133
114. Shearman, A. M., Cupples, L. A., Demissie, S. et al. (2003) Association between estrogen receptor α gene variation and cardiovascular disease. JAMA, J. Am. Med. Assoc. 290, 2263-2270